No Data
No Data
News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
Adaptimmune Completes Merger With Fellow Immunology Company TCR2
Adaptimmune Announces Completion of Strategic Combination With TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 1, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR2 Therapeutics Inc. (NASDAQ: TCRR) to create a preeminent T-cell therapy company to treat solid tumors.
TCR2 Therapeutics Target Price Raised to $2.11 From $1.72 at Mizuho Securities
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in pe
TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities
No Data